Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The ROV (Rapid Onset Vasodilator) protocol refers to a specific combination of pharmacological probes used in clinical research by the University of Wisconsin, Madison, to investigate microvascular function and peripheral vasodilation in obese individuals. The protocol utilizes a multi-component approach to dissect vasodilatory mechanisms, specifically targeting potassium-mediated pathways, nitric oxide bioavailability, and prostaglandin signaling. The primary components include barium chloride (a KIR channel blocker), L-NMMA (a nitric oxide synthase inhibitor), ketorolac (a cyclooxygenase inhibitor), and adenosine triphosphate (ATP). This experimental setup is designed to evaluate how obesity alters endothelial-dependent and functional vasodilation in skeletal muscle.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ROV protocol pharmacological probes.